RadnostixINIS -2.66% Days Payable is 126.06 as of Mar. 2026, which is 20% above its 10-year median of 104.77. The stock has 3 warning signs investors should review. Among 920 Drug Manufacturers companies, Radnostix ranks worse than 57.28% on this metric.
Radnostix's average Accounts Payable for the
three
months ended in Mar. 2026 was $1.70 Mil. Radnostix's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $1.23 Mil.
Hence, Radnostix's Days Payable for the
three
months ended in Mar. 2026 was 126.06.
The historical rank and industry rank for Radnostix's Days Payable or its related term are showing as below:
INIS'
s Days Payable Range Over the Past 10 Years
Min: 35.17 Med: 104.77 Max: 296.49
Current: 79.52
During the past 13 years, Radnostix's highest Days Payable was 296.49. The lowest was 35.17. And the median was 104.77.
INIS's Days Payable is ranked worse than 57.28% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs INIS: 79.52
Radnostix's Days Payable
increased
from Mar. 2025 (44.76) to Mar. 2026 (126.06).
It may suggest that Radnostixdelayed paying its suppliers.
Radnostix Days Payable Related Terms
Radnostix Days Payable Historical Data
* Premium members only.
The historical data trend for Radnostix's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Radnostix's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radnostix Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Radnostix's Days Payable distribution charts can be found below:
* The bar in red indicates where Radnostix's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Radnostix's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radnostix (INIS) has a Days Payable of 126.06 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Radnostix and its competitors. This is 20% above median its historical median of 104.77. Over the past decade, Radnostix's Days Payable has ranged from 35.17 to 296.49. According to the industry distribution chart, Radnostix ranks #527 out of 920 companies in the Drug Manufacturers industry, placing it in the top 57.3%.
Is Radnostix's Days Payable too high?
Radnostix's current Days Payable of 126.06 is 20% above median its 10-year median of 104.77. Over the past 10 years, this metric has ranged from a low of 35.17 to a high of 296.49. The Drug Manufacturers industry median Days Payable is 90.84. Radnostix's value of 126.06 is 38.8% above this industry median. Based on the distribution chart, Radnostix ranks #527 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Radnostix's Days Payable compare to SCYX and BTAI?
According to the Drug Manufacturers industry distribution chart, Radnostix ranks #527 out of 920 companies for Days Payable. This places Radnostix in the lower half of its industry. The industry median Days Payable is 90.84. Radnostix's value of 126.06 is 38.8% above this benchmark. Historically, Radnostix's own Days Payable has ranged from 35.17 to 296.49 over the past decade. While the company's 10-year median is 104.77 vs. the industry median of 90.84, Radnostix has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Radnostix's current Days Payable of 126.06 is 38.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Radnostix and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radnostix's current Days Payable is 126.06, which is 20% above median its own 10-year median of 104.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radnostix stock overvalued right now?
Based on GuruFocus' analysis, Radnostix (INIS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 40% above its estimated fair value. The current Days Payable is 126.06, which is 20% above median its 10-year median of 104.77 and 38.8% above the Drug Manufacturers industry median of 90.84. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Radnostix (INIS), the current Days Payable is 126.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Radnostix Inc manufactures a wide range of radioisotope-focused products used in a variety of medical and industrial applications. The company produces generic sodium iodide I-131 drug product, produces a variety of cobalt-60 products, and is in development to manufacture and sell medical devices for the nuclear medicine industry. Its business consists of five reportable segments, which include: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The majority of the revenue is derived from the Theranostics Products segment, which produces and distributes various isotopically pure radiopharmaceuticals, APIs, and radiochemicals for medical, industrial, and research applications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INIS has been successfully added to your 